TFB2M

Across TCGA pan-cancer cohorts, TFB2M mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TFB2M data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TFB2M mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TFB2M expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

CCRCC, HNSC, and PDAC are the cancer types where TFB2M mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.430	0.823	.002	35	view →
HNSC	OS	Quartile	All	0.756	0.923	.008	18	view →
PDAC	DFS	Tertile	All	0.345	0.539	.020	10	view →
GBM	OS	Median	All	0.667	0.378	.018	8	view →
LUAD	DFS	Median	II,III,IV	0.959	0.713	.015	3	view →
LSCC	DFS	Quartile	II,III,IV	0.860	0.499	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TFB2M–CCRCC (DFS)

Open the CCRCC breakdown →